QALY Control: House Bill Would Ban Cost-Effectiveness Tool In US Programs
No one seems eager to defend the QALY tool as a House Republican bill seeks to prohibit any federal agency from using Quality Adjusted Life Years as a formula to determine pricing.
You may also be interested in...
Rodgers Takes House Energy And Commerce Helm Criticizing ‘Administration Gone Woke’
Day after taking chair of committee with FDA oversight, Rodgers criticizes White House’s declaration extending COVID-19 public health emergency. House Appropriation chair Granger prioritizes cutting spending, boosting military.
HHS Drug Pricing Plan: Mum On National Cost Effectiveness Program, Cautious On QALYs
Biopharma likely approves of the Administration’s concern that QALYs, a commonly used metric in cost effectiveness evaluations, may not be appropriate for drug pricing reform policies because it could disadvantage people with disabilities.
Moderna And The All-American Drug Pricing Hearing
Moderna’s time in the hot seat of the US drug pricing debate went about as well as it could for the company. The firm astutely set a tone of an All-American success story – but the hearing also showcased other ‘only in America’ themes.